ARQL
ArQule, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.
Market Cap: 2.42 Billion
Primary Exchange: NASDAQ
Website: http://www.arqule.com
Shares Outstanding: 121 Million
Float: 109 Million
Dividend: (%)
Beta: 0.5780445225519669
Sector: Health Technology
Industry: Pharmaceuticals: Other
Ethical Flags
Longest drawdown: 1231 trading days
From: 2013-04-25 To: 2018-03-23
Lowest Point:
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
via: Business Wire at 2019-06-10 03:00:00:000
Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the companys phase 1/2 stud… read more...
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
via: Business Wire at 2019-06-10 03:00:00:000
Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the companys phase 1/2 stud… read more...
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
via: Business Wire at 2019-06-10 03:00:00:000
Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the companys phase 1/2 stud… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|